AstraZeneca taps 20-plus partners to hit goal of 2bn COVID-19 vaccines 06-Aug-2020 By Nick Taylor AstraZeneca creates “parallel supply chains” through partnerships to support rapid scaling up of COVID-19 vaccine capacity.
Lilly: Maximizing manufacturing capacity is key to COVID-19 antibody strategy 04-Aug-2020 By Nick Taylor Eli Lilly cites need to maximize production capacity to explain decision to develop a single-antibody candidate against COVID-19.
Sangamo and Novartis partner on gene therapies for autism 03-Aug-2020 By Ben Hargreaves The two companies will develop three neurodevelopmental targets, using the former’s zinc-finger technology.
Fujifilm to produce COVID-19 vaccines, BARDA speeds up capacity boost 03-Aug-2020 By Ben Hargreaves US BARDA drafts Fujifilm Diosynth into its vaccine production effort, offering to also accelerate capacity expansion.
Moderna enters P3 trials for vaccine, with $483m BARDA push 30-Jul-2020 By Ben Hargreaves US government supports Moderna’s clinical program for its COVID-19 vaccine with financial backing.
Fujifilm Diosynth partners with Novavax to manufacture COVID-19 vaccine 28-Jul-2020 By Ben Hargreaves Novavax utilizes US government funds to agree the manufacture of bulk drug substance for potential vaccine.
Ireland calls attention to cell and gene infrastructure 22-Jul-2020 By Ben Hargreaves A report by IDA outlines investment made by biopharma into cell and gene development and manufacturing capabilities.
MassBio wants improved manufacturing to maintain biohub position 22-Jul-2020 By Ben Hargreaves The organization calls for capabilities to manufacture advanced therapeutics, such as cell and gene therapies.
Marken adds multiple depot locations, boosts capacity for cell and gene 21-Jul-2020 By Ben Hargreaves Marken announces the addition of two depots in the US and Ukraine, as well as logistics branches in Ireland and the Netherlands.
Catalent to invest $30m on clinical manufacturing site in France 21-Jul-2020 By Ben Hargreaves The company invests into its clinical biologics formulation development and drug fill-finish services.
Merck KGaA takes up option to license bispecific antibody 20-Jul-2020 By Ben Hargreaves The company opts into its second bispecific antibody through its partnership with F-star Therapeutics.
Moderna releases positive early vaccine data, signs fill-finish deal 16-Jul-2020 By Ben Hargreaves The biotech provides more detail on Phase I study of its COVID-19 vaccine and agrees commercial fill-finish manufacturing.
Merck CEO: COVID-19 vaccine manufacture and distribution ‘huge issue’ 15-Jul-2020 By Ben Hargreaves Kenneth Frazier states manufacture of potential vaccine is ‘bigger challenge’ than developing an effective vaccine.
Takeda deal looks to bolster biologics pipeline 14-Jul-2020 By Ben Hargreaves Takeda partners with Twist Bioscience for access to platform to discover, validate and optimize antibodies in its pipeline.
Dewpoint and Merck in $305m deal for HIV ‘cure’ 14-Jul-2020 By Ben Hargreaves The two partners will use Dewpoint’s platform, focusing on biomolecular condensates, to treat the disease.
